Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway

Abstract We recently demonstrated that tissue kallikrein (TK) promotes keratinocyte migration through activation of protease-activated receptor-1 (PAR1) and transactivation of the epi-dermal growth factor receptor (EGFR). In this study, we investigated the potential role of PAR1 in mediating the effect of TK on cancer cell migration, invasion and proliferation. Our results show that TK promotes DU145 prostate cancer cell migration in a concentration-dependent manner, but has no effect on A549 lung cancer cells. Active TK markedly increases DU145 cell migration and invasion, which are blocked by aprotinin but minimally affected by icatibant; kinin treatment has little effect. TK-induced cell migration and invasion are abolished by inhibition of PAR1 using a pharmacological inhibitor or RNA interference. The effect of TK on cell migration and invasion are also blocked by inhibitors of protein kinase C, c-Src, matrix metalloproteinase, EGFR and extracellular signal-regulated kinase (ERK). Moreover, TK stimulates ERK phosphorylation, which is inhibited by an EGFR antagonist. Additionally, TK but not kinin stimulates DU145 cell proliferation through activation of the kinin B2 receptor, but not PAR1 and EGFR. These results indicate differential signaling pathways mediated by TK in promoting prostate cancer cell migration and invasion via PAR1 activation, and proliferation via kinin B2 receptor stimulation.

[1]  L. Chao,et al.  A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. , 2010, Experimental cell research.

[2]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[3]  L. Chao,et al.  Tissue Kallikrein Elicits Cardioprotection by Direct Kinin B2 Receptor Activation Independent of Kinin Formation , 2008, Hypertension.

[4]  T. Cocks,et al.  B2 kinin receptor activation is the predominant mechanism by which trypsin mediates endothelium-dependent relaxation in bovine coronary arteries , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  M. Jaramillo,et al.  Differential sensitivity of A549 non small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors , 2008, Cancer biology & therapy.

[6]  J. Noh,et al.  Lysophosphatidylcholine stimulates EGF receptor activation and mesangial cell proliferation: regulatory role of Src and PKC. , 2007, Biochimica et Biophysica Acta.

[7]  J. Siegfried,et al.  Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. , 2006, Cancer research.

[8]  E. Diamandis,et al.  Proteinase-activated Receptors, Targets for Kallikrein Signaling* , 2006, Journal of Biological Chemistry.

[9]  H. Larjava,et al.  HaCaT keratinocyte migration is dependent on epidermal growth factor receptor signaling and glycogen synthase kinase-3alpha. , 2006, Experimental cell research.

[10]  R. Isseroff,et al.  beta-Adrenergic receptor antagonists accelerate skin wound healing: evidence for a catecholamine synthesis network in the epidermis. , 2006, The Journal of biological chemistry.

[11]  E. Diamandis,et al.  Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs) , 2006, Biological chemistry.

[12]  E. Diamandis,et al.  Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more , 2006, Biological chemistry.

[13]  K. Sayama,et al.  A Novel Function of Angiotensin II in Skin Wound Healing , 2006, Journal of Biological Chemistry.

[14]  P. Deddish,et al.  Kallikrein activates bradykinin B2 receptors in absence of kininogen. , 2006, American journal of physiology. Heart and circulatory physiology.

[15]  N. Saijo,et al.  Dimerization and the signal transduction pathway of a smallin‐frame deletion in the epidermal growth factor receptor , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  B. H. Shah,et al.  Role of metalloproteinase‐dependent EGF receptor activation in α1‐adrenoceptor‐stimulated MAP kinase phosphorylation in GT1‐7 neurons , 2006, Journal of neurochemistry.

[17]  D. Haskard,et al.  Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. , 2006, The Journal of thoracic and cardiovascular surgery.

[18]  M. Hollenberg,et al.  Neutrophils and the kallikrein–kinin system in proteinase‐activated receptor 4‐mediated inflammation in rodents , 2005, British journal of pharmacology.

[19]  K. Pienta,et al.  PAR1‐mediated NFκB activation promotes survival of prostate cancer cells through a Bcl‐xL‐dependent mechanism , 2005, Journal of cellular biochemistry.

[20]  A. Yoshimura,et al.  Induction of Keratinocyte Migration via Transactivation of the Epidermal Growth Factor Receptor by the Antimicrobial Peptide LL-371 , 2005, The Journal of Immunology.

[21]  A. Ullrich,et al.  GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways , 2005, Biological chemistry.

[22]  G. Stamp,et al.  Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. , 2004, Neoplasia.

[23]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[24]  C. Pothoulakis,et al.  Metalloproteinases and Transforming Growth Factor-α Mediate Substance P-induced Mitogen-activated Protein Kinase Activation and Proliferation in Human Colonocytes* , 2004, Journal of Biological Chemistry.

[25]  M. Laburthe,et al.  Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. , 2004, Molecular cancer research : MCR.

[26]  E. Baldi,et al.  The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells , 2004, Steroids.

[27]  H. Matsubara,et al.  Host Stromal Bradykinin B2 Receptor Signaling Facilitates Tumor-Associated Angiogenesis and Tumor Growth , 2004, Cancer Research.

[28]  G. Conner,et al.  Role of Hyaluronan and Reactive Oxygen Species in Tissue Kallikrein-mediated Epidermal Growth Factor Receptor Activation in Human Airways* , 2004, Journal of Biological Chemistry.

[29]  E. Diamandis,et al.  Human tissue kallikreins: physiologic roles and applications in cancer. , 2004, Molecular cancer research : MCR.

[30]  T. Peretz,et al.  Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Lee Chao,et al.  Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.

[32]  A. Sabri,et al.  Protease-Activated Receptor-1–Mediated DNA Synthesis in Cardiac Fibroblast Is via Epidermal Growth Factor Receptor Transactivation: Distinct PAR-1 Signaling Pathways in Cardiac Fibroblasts and Cardiomyocytes , 2002, Circulation research.

[33]  S. Yamashina,et al.  Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. , 2002, International immunopharmacology.

[34]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[35]  H. Oosterkamp,et al.  The androgen receptor and estrogen receptor , 2002 .

[36]  A. Kalmes,et al.  EGFR Transactivation in the Regulation of SMC Function , 2001, Annals of the New York Academy of Sciences.

[37]  L. Chao,et al.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. , 2001, The American journal of pathology.

[38]  K. Bhoola,et al.  Kallikrein and kinin receptor genes. , 2000, Pharmacology & therapeutics.

[39]  E. G. Erdös,et al.  Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. , 2000, Molecular pharmacology.

[40]  Robert V Farese,et al.  Normal Development, Wound Healing, and Adenovirus Susceptibility in β5-Deficient Mice , 2000, Molecular and Cellular Biology.

[41]  C. Martínez-A,et al.  The Matrix Metalloproteinase-9 Regulates the Insulin-like Growth Factor-triggered Autocrine Response in DU-145 Carcinoma Cells* , 1999, The Journal of Biological Chemistry.

[42]  A. Ullrich,et al.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.

[43]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[44]  C. Soria,et al.  Activation of the 92 kDa type IV collagenase by tissue kallikrein , 1993, Journal of cellular physiology.

[45]  L. Juliano,et al.  Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing. , 1992, Biochemistry.

[46]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[47]  N. Rhaleb,et al.  Kinin Receptor Subtypes , 1990, Journal of cardiovascular pharmacology.

[48]  H. Tschesche,et al.  Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. , 1989, Advances in experimental medicine and biology.

[49]  K. Nustad,et al.  Enzymatic activity of rat submandibular gland kallikrein released into blood. , 1985, The American journal of physiology.

[50]  T. Miyata,et al.  Demonstration of arginyl-bradykinin moiety in rat HMW kininogen: direct evidence for liberation of bradykinin by rat glandular kallikreins. , 1985, Biochemical and Biophysical Research Communications - BBRC.

[51]  K. Shimamoto,et al.  Kallikrein-induced uterine contraction independent of kinin formation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Shimamoto,et al.  The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements. , 1980, The Journal of clinical endocrinology and metabolism.

[53]  J. Chao,et al.  Isozymes of rat urinary kallikrein. , 1979, Biochemical pharmacology.

[54]  F. Fiedler.  Enzymology of Glandular Kallikreins , 1979 .